Heidelberg Pharma AG: Interim Statement on the First Three Months of Financial Year 2025
- Cohort 7 of the clinical trial of HDP-101 in multiple myeloma safe and well tolerated
- Cohort 8 expected to start soon
- Clinical development of the second ADC program HDP-102 in patients with non-Hodgkin lymphoma (NHL) has started
- Amendment of contract with HealthCare Royalty; payment of USD 20 million significantly extends cash reach
Ladenburg, Germany, 24 April 2025 – Heidelberg Pharma AG (FSE: HPHA) today reported on the first three months of fiscal year 2025 (1 December 2024 – 28 February 2025) and the Group’s financial figures.
